he merger of Carl Zeiss Ophthalmic Systems and Asclepion-Meditec has been unanimously approved by shareholders, with Zeiss holding 76% of the shares of the new combined firm, called Carl Zeiss Meditec AG, whose equity is being raised by e19.6 million to e25.8 million.